Skip to main content
. 2021 Aug 10;13(16):4025. doi: 10.3390/cancers13164025
AR androgen receptor
ADT androgen deprivation therapy
BAT bipolar androgen therapy
ChIP chromatin immuno-precipitation
CRPC castration-resistant PCa
DHT dihydrotestosterone
hTERT human telomerase reverse transcriptase catalytic subunit
ING1/2 inhibitor of growth 1 and 2
LAL low androgen levels
nARE negative androgen response element
pARE positive androgen response element
PCa prostate cancer
R1881 methyltrienolone
SAL supraphysiological androgen level